Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932268 | 0.82 | FFAR1 (0.52) | FFAR1FFAR4KEAP1AKR1B1S1PR1 | |
| SCHEMBL2475056 | 0.82 | FFAR1 (0.52) | FFAR1FFAR4AKR1B1S1PR1 | |
| SCHEMBL6985623 | 0.82 | FFAR1 (0.65) | FFAR1FFAR4KEAP1AKR1B1S1PR1 | |
| SCHEMBL2827047 | 0.82 | FFAR1 (0.59) | FFAR1FFAR4S1PR1 | |
| SCHEMBL30444612 | 0.82 | FFAR1 (0.65) | FFAR1FFAR4KEAP1AKR1B1S1PR1 | |
| SCHEMBL31395882 | 0.80 | FFAR1 (0.54) | FFAR1FFAR4KEAP1AKR1B1S1PR1 | |
| SCHEMBL3348357 | 0.79 | CYP4F2 (0.54) | FFAR1 | |
| SCHEMBL6184598 | 0.79 | FFAR1 (0.49) | FFAR1FFAR4KEAP1AKR1B1S1PR1 | |
| SCHEMBL4715830 | 0.79 | S1PR1 (0.58) | FFAR1FFAR4KEAP1AKR1B1S1PR1 | |
| SCHEMBL28460083 | 0.78 | FFAR1 (0.57) | FFAR1FFAR4S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2141146-A1 | Calcilytic compounds | SmithKline Beecham Corporation (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-1254106-B1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7109238-B2 | Calcilytic compounds | SMITH KLINE BEECHAM CORPORATION (US) | 2006-09-19 | — | — | US | disclosed |
| EP-1254106-A4 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20040192741-A1 | Calcilytic compounds | SMITHKLINE BEECHAM CORPORATION & NPS PHARMACEUTICALS | 2004-09-30 | — | — | US | disclosed |
| CN-1396906-A | Calcilytic compounds | SMITHKLINE BEECHAM CORP (US) | 2003-02-12 | — | — | CN | disclosed |
| US-20030018203-A1 | Calcilytic compounds | NPS PHARMACEUTICALS, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-1254106-A1 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001053254-A1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018203-A1 | Calcilytic compounds | SOST, CALCB, CALCR | FFAR1 4113/4885FFAR4 4331/4885KEAP1 4006/4885 |
| US-20040192741-A1 | Calcilytic compounds | SOST, CALCB, CALCR | FFAR1 4113/4885FFAR4 4331/4885KEAP1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.